Zielsetzungen palliativmedizinischer Maßnahmen bei Patienten mit malignen Hirntumoren

Eva Katharina Masel; Gudrun Kreye; Stefan Oberndorfer; Christine Marosi

doi:10.1055/a-0734-5771

Zeitschrift für Palliativmedizin, Table of Contents

Zeitschrift für Palliativmedizin 2018; 19(06): 312-321
DOI: 10.1055/a-0734-5771

CME-Fortbildung

Zielsetzungen palliativmedizinischer Maßnahmen bei Patienten mit malignen Hirntumoren

Eva Katharina Masel

,

Gudrun Kreye

,

Stefan Oberndorfer

,

Christine Marosi

Subject Editor: Wissenschaftlich verantwortlich gemäß Zertifizierungsbestimmungen für diesen Beitrag ist Prof. Dr. Christine Marosi, Wien.

Abstract

Die Symptome von Patienten mit bösartigen Hirntumoren unterscheiden sich deutlich von anderen Patienten mit fortgeschrittenen Krebserkrankungen. Anhand von Publikationen und der im Vorjahr publizierten Guidelines der Europäischen Gesellschaft für Neuro-Onkologie (EANO) werden die Besonderheiten bei neuroonkologischen Patienten dargestellt.

Full Text

References

Literatur
1 Louis DN, Perry A, Reifenberger G. et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 2016; 131: 803-820
2 Drappatz J, Schiff D, Kesari S. et al. Medical management of brain tumor patients. Neurol Clin 2007; 25: 1035-1071
3 Pace A, Di Lorenzo C, Capon A. et al. Quality of care and rehospitalization rate in the last stage of disease in brain tumor patients assisted at home: a cost effectiveness study. J Palliat Med 2012; 15: 225-227
4 Pace A, Dirven L, Koekkoek JAF. et al. European Association for Neuro-Oncology (EANO) guidelines for palliative care in adults with glioma. Lancet Oncol 2017; 18: e330-e340
5 Sizoo EM, Braam L, Postma TJ. et al. Symptoms and problems in the end-of-life phase of high-grade glioma patients. Neuro Oncol 2010; 12: 1162-1166
6 Sizoo EM, Dirven L, Reijneveld JC. et al. Measuring health-related quality of life in high-grade glioma patients at the end of life using a proxy-reported retrospective questionnaire. J Neurooncol 2014; 116: 283-290
7 Koekkoek JA, Dirven L, Sizoo EM. et al. Symptoms and medication management in the end of life phase of high-grade glioma patients. J Neurooncol 2014; 120: 589-595
8 Walbert T, Khan M. End-of-life symptoms and care in patients with primary malignant brain tumors: a systematic literature review. J Neurooncol 2014; 117: 217-224
9 in der Schmitten J, Nauck F, Marckmann G. Behandlung im Voraus planen (Advance Care Planning): ein neues Konzept zur Realisierung wirksamer Patientenverfügungen. Z Palliativmed 2016; 17: 177-195
10 Walbert T, Pace A. End-of-life care in patients with primary malignant brain tumors: early is better. Neuro Oncol 2016; 18: 7-8
11 Flechl B, Ackerl M, Sax C. et al. The caregivers’ perspective on the end-of-life phase of glioblastoma patients. J Neurooncol 2013; 112: 403-411
12 Rooney AG, Netten A, McNamara S. et al. Assessment of a brain-tumour-specific Patient Concerns Inventory in the neuro-oncology clinic. Support Care Cancer 2014; 22: 1059-1069
13 Ownsworth T, Chambers S, Hawkes A. et al. Making sense of brain tumour: a qualitative investigation of personal and social processes of adjustment. Neuropsychol Rehabil 2011; 21: 117-137
14 Oberndorfer S, Lindeck-Pozza E, Lahrmann H. et al. The end-of-life hospital setting in patients with glioblastoma. J Palliat Med 2008; 11: 26-30
15 Thier K, Calabek B, Tinchon A. et al. The Last 10 Days of Patients With Glioblastoma: Assessment of Clinical Signs and Symptoms as well as Treatment. Am J Hosp Palliat Care 2016; 33: 985-988
16 Koekkoek JA, Postma TJ, Heimans JJ. et al. Antiepileptic drug treatment in the end-of-life phase of glioma patients: a feasibility study. Support Care Cancer 2016; 24: 1633-1638
17 Vecht CJ. et al. Dose-effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors: a randomized study of doses of 4, 8, and 16 mg per day. Neurology 1994; 44: 675-680
18 Perry JR, Julian JA, Laperriere NJ. et al. PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. J Thromb Haemost 2010; 8: 1959-1965
19 Zwicker JI, Karp Leaf R, Carrier M. A meta-analysis of intracranial hemorrhage in patients with brain tumors receiving therapeutic anticoagulation. J Thromb Haemost 2016; 14: 1736-1740
20 Koekkoek JA, Dirven L, Reijneveld JC. et al. End of life care in high-grade glioma patients in three European countries: a comparative study. J Neurooncol 2014; 120: 303-310
21 Sommer S, Marckmann G, Pentzek M. et al. Patientenverfügungen in stationären Einrichtungen der Seniorenpflege. Vorkommen, Validität, Aussagekraft und Beachtung durch das Pflegepersonal. Deutsches Ärzteblatt 2012; 109: 577-583
22 Nauck F, Becker M, King C. et al. To what extent are the wishes of a signatory reflected in their advance directive: a qualitative analysis. BMC medical ethics 2014; 15: 52
23 Philip J, Collins A, Brand C. et al. A proposed framework of supportive and palliative care for people with high-grade glioma. Neuro Oncol 2018; 20: 391-399